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ABSTRACT  
In spite of compelling evidence linking Aβ disturbances to the pathophysiology of Alzheimer’s disease, 
Aβ based treatments have consistently failed to produce any beneficial effects both in mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD) even with successful reductions of toxic aggregated and 
soluble Aβ species. Before abandoning both the hypothesis and approach, there is a need to examine 
some overlooked factors that may have contributed to the lack of efficacy, such as the potential drug-
induced increases in neuronal hyperactivity leading to adverse cognitive effects. In particular, we posit 
that selective cholinergic and noradrenergic pathways will be especially vulnerable to this adverse effect. 
If confirmed, this idea could help identify a potentially preventable and treatable obstacle for enhancing 
the efficacy of therapeutic agents in MCI and AD. 
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The repeated failure of Aβ-lowering drugs to demonstrate efficacy in the treatment of mild 
cognitive impairment (MCI) and Alzheimer’s disease (AD) have led many pharmaceutical sponsors to 
abandon these approaches, and are posing a serious challenge to the Aβ/amyloid hypothesis of AD 
pathophysiology. However, although several attempts have been made to explain these failures from 
within the amyloid framework [e.g., 1-3], a further explanation has been largely neglected. Namely, that 
this therapeutic failure might have been caused by a potentially treatable complication of these treatments: 
an accentuation of neuronal hyperactivity from successful brain Aβ plaques removal. This hypothesis was 
recently put forward by Busche and colleagues [4, see also 5], but the notion that hyperactivity of certain 
neuronal systems could contribute to the pathophysiology of cognitive dysfunction in AD has an even 
longer publication history [6]. 
In a series of experiments conducted by Busche and colleagues [7] using two-photon Ca2+ imaging 
mouse model of AD, 29% of layer 2/3 cortical neurons showed a reduction in neuronal activity, whereas 
21% showed hyperactivation. They also showed that the appearance of hyperactive neurons correlated 
with the density of plaques and impairments in the animals’ learning ability. Furthermore, they also 
demonstrated that neuronal hyperactivity was decreased by diazepam, an agonist of the GABA-A 
receptor, resulting in enhanced GABAergic tone, and increased by a GABA-A receptor antagonist. Thus, 
these findings suggest that a greater sensitivity of inhibitory GABAergic neurons to the neurotoxic effects 
of soluble factors in the vicinity of plaques mediated the increased hyperactivity of excitatory neurons.  
In a subsequent investigation, the same group [8] provided evidence that increased soluble Aβ 
species, rather than plaques, resulted in neuronal hyperactivation. They demonstrated that hyperactivation 
of hippocampal neurons was present in a young mouse model of AD prior to the development of plaques, 
and that it could be prevented by the administration of the gamma secretase inhibitor LY-411575, which 
decreased soluble Aβ levels. They also showed that direct application of soluble Aβ in wild type mice 
induced neuronal hyperactivity. These results are consistent with findings from a number of preclinical 
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investigations [9, 10] linking soluble Aβ species to a dysfunction of inhibitory cortical interneurons, 
aberrant increases in excitatory activity, and cognitive deficits 
Consistent with preclinical findings [11], Bakker and colleagues [12, 13] reported that in 
individuals with MCI, who showed increased high-resolution fMRI BOLD activation in the left 
hippocampal dentate gyrus/CA3 (DG\CA3) sub-regions and entorhinal cortex following a memory task, 
chronic treatment with a low dose of the marketed anti-epileptic drug levetiracetam resulted in a 
normalization of fMRI BOLD response and improved cognition.   
In a more recent investigation [14], it was reported that administration of monoclonal antibodies 
against Aβ and successful removal of brain amyloid plaques in transgenic AD models, rather than 
producing a reduction in cortical neuronal hyperactivity, as had been previously observed with a 
reduction in soluble Aβ species after gamma secretase inhibition, actually resulted in a pathological 
increase. Additionally, other studies have shown that treatment with BACE1 inhibitors, which may also 
reduce Aβ plaques by targeting prefibrillary Aβ surrounding the plaques [15, 16], may actually correct the 
brain circuit abnormality, neuronal hyperactivity and associated cognitive deficit in a mouse AD model 
[17]. However, as pointed out by these authors, the relevance of these results based on an mouse model of 
AD to humans remains to be established especially since clinical trials with BACE 1 inhibitors (e.g., 
verubecestat, lanabecestat) in MCI and AD have also failed to demonstrate any efficacy. 
In AD, the presence of amyloid plaques is not limited to the neocortex, but also extends to other 
brain areas, including sub-cortical cholinergic and adrenergic nuclei, which suffer extensive degeneration. 
However, studies have demonstrated that concomitant upregulation of selective cholinergic [6, 18-20] and 
adrenergic [21] pathways also may emerge in both MCI and AD. Thus, any drug-induced removal of Aβ 
plaques from these regions may potentially yield even further increases in the activity of selective 
pathways, eventually reaching a tipping point beyond which more activity would exacerbate negative 
outcomes, following an inverse U relationship between activity and performance [22, 23]. However, as no 
direct evidence has been provided so far, in animal models, to test this conjecture, future studies using 
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high field fMRI and other emerging techniques should determine if treatment with BACE1 inhibitors, and 
other amyloid-based treatments, normalize or accentuate neuronal hyperactivity in selective cholinergic 
and noradrenergic pathways implicated in cognition and memory. 
All in all, the observations from the preclinical literature that some amyloid-based treatments can 
induce neuronal hyperactivity and impair cognition, whereas others such as BACE1 inhibitors can 
actually correct these abnormalities, highlight the need to study the effect of these classes of drugs on 
neuronal hyperactivity in AD and MCI – and especially on specific cholinergic and adrenergic pathways 
providing input to the hippocampus, and other brain regions implicated in cognition including attention 
and memory. This endeavor will allow us to determine if neuronal hyperactivity is accentuated in 
conjunction with successful drug-induced reductions in existing or newly formed brain Aβ plaques, and if 
these changes are associated with a worsening or a lack of significant improvement in cognition. 
Abnormal neuronal activity is potentially preventable and treatable. Therefore, if the hypothesized 
association is confirmed, it could provide an approach for overcoming the current limitations of 
potentially disease modifying Aβ-based treatments for MCI and AD and a further assessment of 
Aβ/amyloid hypothesis. 
 
6 
 
ACKNOWLEDGEMENTS 
No financial or material support. 
No conflict of interest. 
 
  
7 
 
REFERENCES 
1. Hardy J, De Strooper B (2017) Alzheimer’s disease: where next for anti-amyloid therapies?. 
Brain 140, 853-855. 
2. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M (2017) Why do trials for Alzheimer’s disease 
drugs keep failing? A discontinued drug perspective for 2010-2015. Expert opinion on 
investigational drugs 26, 735-739. 
3. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's 
disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery 10, 698. 
4. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Förstl H, Konnerth 
A (2015) Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in 
Alzheimer's models. Nature neuroscience 18, 1725.  
5. Zott B, Busche MA, Sperling RA, Konnerth A (2018) What Happens with the Circuit in 
Alzheimer's Disease in Mice and Humans?. Annual review of neuroscience 41, 277-297. 
6. Pomara N, Bagne CA, Stanley M, Yarbrough GG (1986) Prospective strategies for cholinergic 
interventions in Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 10, 553-569. 
7. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel 
M, Konnerth A, Garaschuk O (2008) Clusters of hyperactive neurons near amyloid plaques in a 
mouse model of Alzheimer's disease. Science 321, 1686-1689.  
8. Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A (2012) 
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of 
Alzheimer's disease. Proc Natl Acad Sci USA 109, 8740-8745.  
8 
 
9. Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in 
Alzheimer's disease: two faces of the same coin? Neuromolecular Med 12, 48-55.  
10. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, 
Mody I, Mucke L, Palop JJ (2012) Inhibitory interneuron deficit links altered network activity 
and cognitive dysfunction in Alzheimer model. Cell 149, 708-721.  
11. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop 
JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses 
synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 109, 
2895-2903. 
12. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, 
Shelton AL, Gallagher M (2012) Reduction of hippocampal hyperactivity improves cognition in 
amnestic mild cognitive impairment. Neuron 74, 467-474.  
13. Bakker A, Albertb MS, Kraussb G, Specka CL, Gallagherc M (2015) Response of the medial 
temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed 
by fMRI and memory task performance. NeuroImage: Clinical 7, 688–698. 
14. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Förstl H, Konnerth A 
(2015) Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's 
models. Nat Neurosci 18, 1725-1727. 
15. Meier SR, Syvänen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, Neumann U, Sehlin D 
(2018) Antibody-based in vivo PET imaging detects amyloid-β reduction in Alzheimer transgenic 
mice after BACE-1 inhibition. J Nucl Med. 118 [Epub ahead of print] 
9 
 
16. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek 
C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D (2018) Randomized 
Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 378, 1691-1703. 
17. Keskin AD, Kekuš M, Adelsberger H, Neumann U, Shimshek DR, Song B, Zott B, Peng T, 
Förstl H, Staufenbiel M, Nelken I (2017) BACE inhibition-dependent repair of Alzheimer's 
pathophysiology. Proc Natl Acad Sci USA 114, 8631-8636. 
18. Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, Nemeroff CB (1990) Regulatory changes 
in presynaptic cholinergic function assessed in rapid autopsy material from patients with 
Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci USA 87, 2452-
2455. 
19. Pomara N, Stanley M, LeWitt PA, Galloway M, Singh R, Deptula D (1992) Increased CSF  
HVA response to arecoline challenge in Alzheimer's disease. J Neural Transm Gen 
Sect 90, 53-65.  
20. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, 
Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase 
activity in hippocampus and frontal cortex of elderly subjects with mild 
cognitive impairment. Ann Neurol 51, 145-155. 
21. Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, Raskind MA (1997) Effects of 
Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J 
Psychiatry 154, 25-30. 
22. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris PP, Haxby JV (1993) Memory 
improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's 
disease. Psychopharmacology 112, 421-427.  
10 
 
23. Introini-Collison IB, Castellano C, McGaugh JL (1994) Interaction of GABAergic and beta-
noradrenergic drugs in the regulation of memory storage. Behav Neural Biol 61, 150-155.  
 
